Shi J, Willemze A, Janssen GM, van Veelen PA, Drijfhout JW, Cerami A, et al
[DOI] [PMC free article] [PubMed] [Google Scholar] 206.Naveed Z., Velasquez Garcia H.A., Wong S., Wilton J., McKee G., Mahmood B., Binka M., Rasali D., Janjua N.Z
Tayang: TRIBUNNEWS.COM, JAKARTA Badan Pengawas Obat dan Makanan (BPOM) RI menemukan peredaran suplemen kesehatan ilegal bermerek Dr
Benefits and Advantages Governed primarily by state boards of pharmacy rather than federal manufacturing regulations Typically meet minimum industry standards set by USP Overall lower regulatory risk compared to 503B May have a greater number of formulation offerings due to lower development costs, allowing for a wider variety of dosing options and formulations Lower initial startup cost compared to starting a 503B Lower operational requirements compared to 503Bs Faster time to market for new compounding services Lower annual fees (primarily state licensing fees, compared to significant annual FDA establishment and potential reinspection fees for 503Bs) Can focus on developing a local business or scaling and targeting the broader market Personalized patient care, tailored formulations for specialized treatment plans and patient needs, consultation opportunities Significant growth and scale-up opportunities Strong revenue potential through niche markets and personalized formulations Challenges and Disadvantages Cant produce batches of CSPs in excess of 250 units Can supply compounded medications only under patient-specific conditions Patients often have to cover medication costs out-of-pocket Not subject to the same batch test release requirements under federal cGMP, but expected to ensure quality through USP- and/or state board of pharmacy-compliant procedures and documentation Can a 503A Pharmacy Purchase Products Compounded by a 503B Facility
Anti-estrogen-based endocrine therapies, such as the ER modulator Tamoxifen, ER degrader Fulvestrant, and the aromatase inhibitor Letrozole, have significantly enhanced the survival rates of patients with hormone receptor-positive (HR+) breast cancer [5]
